Orexigen Gives The Skinny On Obesity Market During Contrave Update
This article was originally published in The Pink Sheet Daily
Executive Summary
Orexigen discussed the dynamics of the obesity market as its 9,000-patient cardiovascular outcomes study for the diet pill Contrave gets underway.